Prompt initiation of pharmacotherapy benefits patients with interstitial cystitis
This article has no abstract so we have provided the first paragraph of the full text.
Interstitial cystitis (IC) is a painful, chronic bladder syndrome that is often diagnosed late—partly because the symptoms are shared with common conditions—and treated after considerable delay. Although pharmacologic treatment has proven ineffective for many patients with IC, pentosan polysulfate sodium (PPS) seems to be beneficial. In a post-hoc analysis of data from a randomized trial, Nickel et al. examined whether the interval between diagnosis of IC and initiation of PPS (300 mg daily for 32 weeks) affected the extent of symptomatic improvement.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.